Marks C, Marks JD. 1996. Phage libraries-a new route to clinically useful antibodies. New England Journal of Medicine 335: 730–733.

Mendez MJ, Green LL, Corvalan JR, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genetics 15:146–156.

Montecucco C. 1986. How do tetanus and botulinum toxins bind to neuronal membranes? Trends in Biochemical Science 11: 315–317.

Montecucco C, Schiavo G. 1995. Structure and function of tetanus and botulinum neurotoxins. Quarterly Review of Biophysics 28, 423–472.

Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. 1984. Proceeding of the National Academy of Sciences, USA. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. 81:643–646.

Mullaney BP, Pallavicini MG, Marks JD. 2001. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infection and Immunity 69:6511–6514.

Nowakowski A, Wang C, Powers D, Amersdorfer P, Smith T, Montgomery V, Sheridan R, Blake R, Smith L, Marks JD. (In press) . Deconvoluting the immune response: Potent botulinum neurotoxin neutralization by oligoclonal antibody.


Pless DD, Torres ER, Reinke EK, Bavari S. 2001. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infection and Immunity 69:570–574.


Reichert J.M. 2001. Monoclonal antibodies in the clinic. Nature Biotech 19: 819–822.


Schiavo G, Benfenati FBP, Rossetto O, Polverino DLP, DasGupta BR, Montecucco C. 1992. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832–835.

Schiavo G, Rossetto O, Catsicas S, Polverino DLP, DasGupta BR, Benfenati F, Montecucco C. 1993.. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. Journal of Biological Chem 268, 23784–23787.

Schier R, McCall A., Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks J. D. 1996. Isolation of picomolar affinity anti-c-erB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. .Journal of Molecular Biology 263, 551–567.

Sheridan RE, Deshpande SS, Amersdorfer P, Marks JD, Smith T. 2001. toxicon Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. 39, 651–657.

Siegel LS. J. Clin. Microbiol. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 26: 2351–2356.

Simpson LL. 1980. Kinetic studies on the interaction between botulinum toxin type A and the chloinergic neuromuscular junction. Journal of Pharmacological Experimental Therapy 212:16–21.

St. John R, Finlay B, Blair C. 2001. Bioterrorism in Canada: An economic assessment of prevention and postattack exposure. Canadian Journal of Infectious Diseases 12:275–284.


United Nations Security Council. 1995 Tenth report of the executive committee of the special commission established by the secretary-general pursuant to paragraph 9(b)(I) of security council resolution 687 (1991), and paragraph 3 of resolution 699 (1991) on the activities of the Special Commision., New York, NY.


Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664–1666.


Zilinskas RA. 1997. Journal of the American Medical Association. Iraq’s biological weapons: the past as future? 278, 418–424.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement